BNTX

BioNTech SE (BNTX)

Last Price$122.90.6%
Market Cap$29.5B
LTM Net Debt
($18.3B)
YoY Growth
+10.1%
3Y CAGR
+95.9%
5Y CAGR
+105.1%
Stock quality & Intrinsic value
6/10
33.5% undervalued

BioNTech SE Net Debt

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Net Debt
($321.0M)
($206.9M)
($471.3M)
($582.4M)
($1,249.8M)
($1,843.1M)
($15.0B)
($17.8B)
BNTX
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for BNTX and see if it's the right time to invest.
Dive in

BioNTech SE (BNTX) Net Debt comparison analysis

Crunching data... Almost there!

BNTX key stats

USD
EUR
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

Loved by
investors
worldwide
10K+
Investors use our platform
#1
Top value investing hub with all necessary tools
1K+
Experienced investors in our community
4.9
Average rating across all rating platforms

FAQ

1) What is BioNTech SE's Net Debt?

As of today, BioNTech SE's last 12-month Net Debt is ($18.3B), based on the financial report for Sep 30, 2024 (Q3 2024).

2) What is BioNTech SE's Net Debt growth rate?

Over the last year, BioNTech SE's Net Debt growth was 10.1%. The average annual Net Debt growth rates for BioNTech SE have been 190.5% over the past three years, 105.1% over the past five years.

3) Is BioNTech SE's Net Debt growth rate Good?

Over the last year, BioNTech SE's Net Debt growth was 10.1%, which is higher than industry growth of (0.1%). It indicates that BioNTech SE's Net Debt growth is Bad.

4) How does BioNTech SE's Net Debt growth rate compare to its peers?

Over the last year, BioNTech SE's Net Debt growth was 10.1%, which is higher than peer median growth of (45.7%). The list of peers includes MRNA, ALNY, BGNE, INCY, GMAB, NVO, UTHR, VRTX, REGN, ARGX etc.